Regulatory Drug Approval
Formal review of evidence on quality, safety, and efficacy before medicines are authorized for clinical use.
Core metadata
- ID: regulatory_drug_approval
- Era: Modern
- First known date: 1968 (decade)
- Region: United States, Europe, and global medicines regulation
- Review status: source_checked
- Maturity: established
Prerequisites
- Good Manufacturing Practice (good_manufacturing_practice)
- Phase I-III Clinical Trials (phase_i_iii_clinical_trials)
- Public Health Statistics (public_health_statistics)
Dependents
Fields
Field lanes
- Pharmaceuticals & Drug Development: Clinical Development & Regulation
Node sources
- The Drug Development Process (U.S. Food and Drug Administration, 2026, official_agency) • Supports: node, maturity
Prerequisite edge evidence
Edge/source evidence summary:
- Prerequisite edges: 3
- Average edge confidence: 81%
- Prerequisite sources: 3
- expert_inference: 3
| Prerequisite | Type | Confidence | Evidence level | Note | Sources |
|---|---|---|---|---|---|
| Phase I-III Clinical Trials (phase_i_iii_clinical_trials) | required | 90% | expert_inference | Modern drug approval requires clinical evidence on safety and effectiveness from phased human studies or accepted equivalents. |
|
| Good Manufacturing Practice (good_manufacturing_practice) | required | 86% | expert_inference | Approval depends on evidence that the product can be manufactured under controlled quality systems. |
|
| Public Health Statistics (public_health_statistics) | enabling | 68% | expert_inference | Public Health Statistics provides a capability that enables this technology without being the only possible path. |
|
This page is generated from canonical era JSON and is indexable by URL.